Subject: Malcolm T. Brown

Subject of Interest

Malcolm T. Brown is a partner at Wolf Haldenstein. He graduated from University of Pennsylvania (B.A.1988) and Rutgers University School of Law (J.D. 1994). His practice areas include: Foreign Securities Litigation, U.S. Securities Litigation, Derivative Litigation, Corporate Takeover Litigation, Unfair & Deceptive Practices, Defective Products, and Civil Rights. His bar admissions are : State of New York, State of New Jersey, Commonwealth of Pennsylvania, U. S.  District Courts for the Southern, Eastern and Northern Districts of New York,, District of New Jersey, Eastern District of Pennsylvania, and U.S. Court of Appeals for the Second Circuit.

Biography

Wolf Haldenstein Adler Freeman & Herz LLP

Subject: Sherrod Brown (D-OH)

Subject of Interest

U. S. Senator Sherrod Brown (D-OH) is a minority member of the US Senate Committee on Banking. He was elected to the Senate in 2007. Prior to serving in the United States Senate, Brown served as a United States Representative for the 13th District, Ohio’s Secretary of State, a member of the Ohio General Assembly, and has taught in Ohio’s public schools and at The Ohio State University. He also serves on the Senate Committee on Finance and has served on the Senate Agriculture, Nutrition, and Forestry Committee, and he served Chairman of the Subcommittee on Jobs, Rural Economic Growth and Energy Innovation.

Biography

United States Senate Committee on Banking

Subject: Sherrod Brown (D-Ohio)

Subject of Interest

U.S. Senator Sherrod Brown (D-Ohio), is the Ranking Member of the US Senate Committee on Banking. He is now serving in his second term and also serves on the Senate’s Agriculture, Finance, and Veterans Committees. Prior to serving in the United States Senate, Brown served as a United States Representative for the 13th District, Ohio’s Secretary of State, a member of the Ohio General Assembly, and taught in Ohio’s public schools and at The Ohio State University.

Biography 

United States Senate Committee on Banking

 

 

Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Article - Media

H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

 

Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Article - Media

H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED:Video: Ekso Bionics Killed by Naked Short Sellers – Thank You, HCWainwright for Front-Running Their Death

Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)

Article - Media

H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)

Christine Brown

SmarterAnalyst, 29 April 2020

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 8.2% and a 41.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED:

Article: Bank of America Eroded U.S. Spoof Case, Laying Path for JPMorgan

Article - Media

Bank of America Eroded U.S. Spoof Case, Laying Path for JPMorgan

Tom Schoenberg

Bloomberg, 20 February 2020

Bank of America Corp.’s lawyers came through big for their client last year when they whittled down a U.S. case over precious metals spoofing.

Justice Department prosecutors wanted to bring criminal charges, but bank lawyers asked for none and prevailed. Prosecutors named Bank of America throughout the draft settlement document but not in the final version.

Read full article.

Article: Secrets and Lies of the Bailout

Article - Media

Secrets and Lies of the Bailout

Matt Taibbi

Rolling Stone, 4 January 2013

It has been four long winters since the federal government, in the hulking, shaven-skulled, Alien Nation-esque form of then-Treasury Secretary Hank Paulson, committed $700 billion in taxpayer money to rescue Wall Street from its own chicanery and greed. To listen to the bankers and their allies in Washington tell it, you’d think the bailout was the best thing to hit the American economy since the invention of the assembly line. Not only did it prevent another Great Depression, we’ve been told, but the money has all been paid back, and the government even made a profit. No harm, no foul – right?

Read full article.

Article: The Secret Bailout of J. P. Morgan: How Insider Trading Looted Bear Stearns and the American Taxpayer

Article - Media

The Secret Bailout of J. P. Morgan: How Insider Trading Looted Bear Stearns and the American Taxpayer

Ellen Brown

Global Research, 14 May 2008

The mother of all insider trades was pulled off in 1815, when London financier Nathan Rothschild led British investors to believe that the Duke of Wellington had lost to Napoleon at the Battle of Waterloo. In a matter of hours, British government bond prices plummeted. Rothschild, who had advance information, then swiftly bought up the entire market in government bonds, acquiring a dominant holding in England’s debt for pennies on the pound. Over the course of the nineteenth century, N. M. Rothschild would become the biggest bank in the world, and the five brothers would come to control most of the foreign-loan business of Europe. “Let me issue and control a nation’s money,” Rothschild boasted in 1838, “and I care not who writes its laws.”

Read full article.